Evidence map›Paper›PMID 36650166›Full record

ArticleNature communications2023

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.

R C Coombes, P D Badman, J P Lozano-Kuehne, X Liu, I R Macpherson, I Zubairi, R D Baird, N Rosenfeld, J Garcia-Corbacho, N Cresti and 11 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 2 countries.

R C CoombesDepartment of Surgery and Cancer, Imperial College London, London, UK. c.coombes@imperial.ac.uk.ORCID http://orcid.org/0000-0002-4811-1100
P D BadmanDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-0337-3190
J P Lozano-KuehneDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-7372-0725
X LiuDepartment of Surgery and Cancer, Imperial College London, London, UK.
I R MacphersonCancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Glasgow, UK.ORCID http://orcid.org/0000-0003-4295-8885
I ZubairiCancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Glasgow, UK.
R D BairdMedical Oncology, Addenbrooke's Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre, Cambridge, UK.ORCID http://orcid.org/0000-0001-7071-6483
N RosenfeldMedical Oncology, Addenbrooke's Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre, Cambridge, UK.ORCID http://orcid.org/0000-0002-2825-4788
J Garcia-CorbachoMedical Oncology, Addenbrooke's Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre, Cambridge, UK.ORCID http://orcid.org/0000-0002-6109-8449
N CrestiSir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK.ORCID http://orcid.org/0000-0002-0495-4472
R PlummerSir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK.
A ArmstrongBreast Research Office, The Christie NHS Foundation Trust, Christie Hospital, Manchester, UK.
R AllertonC8 Admin Offices, Russell's Hall Hospital, Russells Hall, UK.
D LandersAstrazeneca, Cheshire, UK.ORCID http://orcid.org/0000-0001-8376-9779
H NicholasDepartment of Surgery and Cancer, Imperial College London, London, UK.
L McLellanECMC Programme Office, Research and Innovation, Cancer Research UK, London, UK.
A LimDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
F MouliereMedical Oncology, Addenbrooke's Hospital, Breast Cancer Research Unit, Cancer Research UK Cambridge Centre, Cambridge, UK.ORCID http://orcid.org/0000-0001-7043-0514
O E PardoDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0003-2223-1435
V FergusonDepartment of Surgery and Cancer, Imperial College London, London, UK.
M J SecklDepartment of Surgery and Cancer, Imperial College London, London, UK. m.seckl@imperial.ac.uk.ORCID http://orcid.org/0000-0003-4078-2599
Imperial College London · GBCancer Research UK · GBBeatson West of Scotland Cancer Centre · GBFreeman Hospital · GBAstraZeneca (United Kingdom) · GBRussells Hall Hospital · GBThe Christie NHS Foundation Trust · GB

Funding

Cancer Research UK 11906Cancer Research UK 20240Cancer Research UK 28292
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36650166
PMCPMC9845345
OpenAlexW4316813017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.